Barriers to insulin initiation and intensification and how to overcome them.
about
Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from JapanImplementation of recommended type 2 diabetes care for people with severe mental illness - a qualitative exploration with healthcare professionalsAn exploration of barriers to insulin initiation for physicians in Japan: findings from the Diabetes Attitudes, Wishes And Needs (DAWN) JAPAN studyDevelopment and validation of the Patient Experience with Treatment and Self-management (PETS): a patient-reported measure of treatment burden.Finalizing a measurement framework for the burden of treatment in complex patients with chronic conditions.Effects of insulin changes on quality of life and glycemic control in Japanese patients with type 2 diabetes mellitus: The insulin-changing study intending to gain patients' insights into insulin treatment with patient-reported health outcomes in acSafety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A1chieve studyFactors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: a qualitative exploration.Diabetes patients' experiences with the implementation of insulin therapy and their perceptions of computer-assisted self-management systems for insulin therapyNew insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfactionMinimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira).Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetesIDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy.Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study.Improving management practices and clinical outcomes in type 2 diabetes study: Prevalence of complications in people with type 2 diabetes in India.Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetesEffect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents.Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month eInitiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: results from an observational studyBasal-bolus Therapy in Patients with Type 2 Diabetes Mellitus in the UK: Patient Characteristics, Treatment Patterns and the Effect of Switching to Premixed Insulin.Roles and relationships between health professionals involved in insulin initiation for people with type 2 diabetes in the general practice setting: a qualitative study drawing on relational coordination theory.How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes.Insulin initiation in type 2 diabetes: what are the treatment regimen options and how can we best help patients feel empowered?A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review.Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetesOnset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.Barriers to and enablers of insulin self-titration in adults with Type 2 diabetes: a qualitative study.What determines treatment satisfaction of patients with type 2 diabetes on insulin therapy? An observational study in eight European countries.Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapyReview of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus.Diabetes quality of care at a university community in Beirut.Factors associated with relational coordination between health professionals involved in insulin initiation in the general practice setting for people with type 2 diabetes.Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?Starting glargine in insulin-naïve type 2 diabetic patients based on body mass index is safeA review of current models for initiating injectable therapy for people with type 2 diabetes in primary careParticipants' experiences of intensifying insulin therapy during the Treating to Target in Type 2 Diabetes (4-T) trial: qualitative interview study.Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care.Insulin therapy attitudes and beliefs of physicians in Middle Eastern Arab countries.
P2860
Q26778763-7B91CEE1-6B9C-4971-A588-C11D37319236Q27310938-1FB3B0D2-1994-46B4-A889-AA99614DBA86Q28728439-40E91383-3ADD-4827-9CE1-CC2ECF5B1E08Q30276056-4A46D81C-74D9-4CB9-A6B4-AF0501272CEDQ30300229-E7D83F18-3567-49F8-9A7A-FC7AC81502FDQ33607730-954DFBF7-4BEB-4A35-BEF0-D17D80F89E8AQ33834266-C8D9181E-BA6C-4AF7-81A8-DC50CE743B4AQ34229076-0A1EFAB8-6186-436A-B7C0-5D675CFE207DQ34509377-263175F5-887C-4217-88BD-790EAF0D2B9FQ34657801-D915F229-5576-4FA1-B5FC-1DB57C4F80E8Q35538347-DC1903AE-EB95-4F8D-964B-3A27EB31C67CQ35563702-90BBD241-E123-4C7A-931B-6C298D4A52F5Q35666228-AA2E0990-0970-4CCD-88C1-8AA1F5473FFFQ36097341-373B1EF9-A8B7-48F9-810A-935B6D5FC312Q36360100-040E3C77-B0AE-43F8-8103-A1738BC51DAEQ36422367-5A2EDC16-3F4F-4DE2-BBF1-DDC2F60D9ED4Q36701281-E81CD2EB-1094-41DE-8D40-8BF8C4DD859BQ36971833-3F6ECA12-0386-4A49-BA63-B394F4C3C9EEQ37236069-E00D7B21-95AC-4460-9C69-7AEC4A444364Q37308905-3783D583-99BC-4792-8C30-D5E91334F1DAQ37365411-DD8DFAFB-BE8C-4EAB-9F93-0A44FED66FEBQ37427317-5E677646-0CE5-4849-BAAE-39B59AE6AD05Q37540939-0C92FFD9-0B5A-40AB-B24B-8C8C21126009Q37771436-B249B756-056E-475A-ABD3-76C4BF8D6799Q38008005-B80B22E2-5C43-4AE7-AD79-44C9C0851C2AQ38095682-337F755D-5BC6-4D37-91FA-F584F8F4ED47Q38115799-0F2A4A14-23CA-4100-893C-2A170C0B6069Q38206231-403BA1ED-E56E-4DA8-B308-A2545CDC93E7Q38559486-3D1B8A04-4101-41FB-9EBE-61677ABF2E0CQ38682071-BFF97F41-F04D-4C6A-A678-0161E0365B95Q38692092-6D490844-8D90-4C85-96EA-BC1CCCD21CF5Q39345916-19AD79EC-343A-45BF-B439-A9DEAAACC4A4Q40924177-76E447FF-F9CA-4AC6-B9DD-CF48E3BC6BFEQ40937952-56A7D41B-412B-4B4C-AE09-AA728DEF357BQ41388779-BD6EFE58-0E91-43F3-9E2C-97F60142BC8FQ41889668-99B72C4C-0B92-4E17-AEB7-D0647CF4E7AEQ42656363-935D78F7-ADB0-4095-B92D-84A062378683Q43328453-A11793EE-272B-4C43-9048-914C090121B6Q43678513-59634870-2C29-409F-8639-71B3D170C1A1Q44074384-704103FA-14E3-478F-81CA-6B23D3A2A40D
P2860
Barriers to insulin initiation and intensification and how to overcome them.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Barriers to insulin initiation and intensification and how to overcome them.
@en
Barriers to insulin initiation and intensification and how to overcome them.
@nl
type
label
Barriers to insulin initiation and intensification and how to overcome them.
@en
Barriers to insulin initiation and intensification and how to overcome them.
@nl
prefLabel
Barriers to insulin initiation and intensification and how to overcome them.
@en
Barriers to insulin initiation and intensification and how to overcome them.
@nl
P1476
Barriers to insulin initiation and intensification and how to overcome them.
@en
P2093
P356
10.1111/J.1742-1241.2009.02176.X
P50
P577
2009-10-01T00:00:00Z